Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study

Acta Oncologica

Volumn 44, Issue 3, 2005, Pages 248-254

  Kümmel, Sherko ^a   Thomas, Anke ^a   Paepke, Stefan ^b   Schwarz, Marion ^c   Heinrich, Georg ^d   Wetzel, Andrea ^e   Elling, Dirk ^f   Kohls, Andreas ^g   Lichtenegger, Werner ^a   Blohmer, Jens Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Department of Gynecology   (Germany)

^d Gynecologic Outpatient Clinic   (Germany)

^e Vivantes Klinikum Hellersdorf   (Germany)

^f Oskar Ziethen Hospital   (Germany)

^g Department of Gynecology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIRUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSCIOUSNESS DISORDER; CONSTIPATION; DERMATITIS; DIARRHEA; DOSE RESPONSE; FATIGUE; FEMALE; FEVER; HUMAN; INFLAMMATORY BREAST CANCER; INOPERABLE CANCER; LEUKOPENIA; LOCALLY ADVANCED BREAST CANCER; NAIL DISEASE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SKINFOLD THICKNESS; STOMATITIS; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOPENIA; LYMPH NODE EXCISION; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SKIN; TAXOIDS;

EID: 21344474550     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510029725     Document Type: Article

References (23)

1. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
2. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.
3. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
4. von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackish C, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999;17: 1999-2005.
5. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9.
6. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997;24(4 Suppl. 10):S10-310.
7. Blohmer JU, Paepke S, Kissner L, Elling D, Fliefe B, Grineisen Y, et al. Dose-intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4d-breast cancer: toxicity, clinical and pathological remission. Zentralbl Gynakol 1999;121:522-5.
8. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-75.
9. Trudeau ME, Crump MR, Latreille J, Pritchard KI, Palmer M, Tu D, et al. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer (MBC). A phase I/II study of the National Cancer Institute of Canada - clinical trials group. Presented at the 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 6-9, 2000. Breast Cancer Res Treat 2000; 64(Abstr no. 536).
10. Ellis GK, Thompson T, Craig V, Rinn K, Gralow J, Livingston RL. Feasibility of full dose docetaxel (Taxotere™) after dose-intensive doxorubicin (Adriamycin™) as adjuvant therapy for high-risk primary breast cancer. Presented at the 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 6-9, 2000. Breast Cancer Res Treat 2000;64(Abstr no. 238).
11. Gluck S. The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 2002;9(2 Suppl.):16-27.
12. Paciucci PA, Raptis G, Bleiweiss I, Weltz C, Lehrer D, Gurry R. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs 2002;13:791-5.
13. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001;6(Suppl 3): 30-5.
14. Tolnai E, Cooper B, Silverman P, Overmoyer B, Moss T. Dose-dense preoperative chemotherapy with sequential doxorubicin (D) and docetaxel (T) for operable and inoperable stage II-IIIB breast cancer. Presented at the 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 6-9, 2000. Breast Cancer Res Treat 2000;64:(Abstr no. 256).
15. von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase lib study. J Clin Oncol 2001;19: 3506-15.
16. Jackisch C, von Minckwitz G, Raab G, Schuette M, Blohmer JU, Hilfrich J, et al. Primary endpoint analysis of the GEPAR-DUO-study - preoperative chemotherapy (PCT) comparing dose-dense versus sequential Adriamycin/docetaxel combination in operable breast cancer (T2-3, N0-2, MO). Presented at the 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 11-14, 2002. Breast Cancer Res Treat 2002;76(Abstr no. 152).
17. Valero V. Primary chemotherapy with docetaxel for the management of breast cancer. Oncology (Huntingt) 2002;16 (6 Suppl 6):35-43.
18. Penault-Llorca F, Sastre X, Fiche M, Simony M, Ledoussal J, Ellore V, et al. Pathological response to neoadjuvant chemotherapy (CT): final results of a prospective randomized trial of 4 AT vs. 4 AC as induction therapy in patients with operable breast cancer using Sataloff classification. Presented at the 22nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 8-11, 1999. Breast Cancer Res Treat 1999;57(Abstr no. 248).
19. Wenzel C, Schmidinger M, Locker GJ, Taucher, Gnant M, Jakesz R, et al. Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0). Wien Klin Wochenschr 1999;111:843-50.
20. The French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000; 18:3115-24.
21. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 2000;355:281-3.
22. Kneuper Hall R, Metzner-Sadurski JK, Marshall M, Howard GR. Early recognition of taxane-associated canaliculitis important in preserving lacrimal duct function. Presented at the 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 6-9, 2000. Breast Cancer Res Treat 2000;64(Abstr no. 356).
23. Jackisch C, von Minckwitz G, Eidtmann H, Costa SD, Raab G, Blohmer JU, et al. Dose-dense biweekly doxorubicin/ docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 2002;3:276-80.